Introduction
============

Osteoarthritis (OA) is a progressively debilitating condition that causes cartilage erosion of the involved joint with pain and functional impairment. Traditional methods to regenerate defects of articular cartilage include microfracture, multiple perforations, abrasions and mosaicplasty, the results of which are not satisfactory[@b1-ksrr-30-206],[@b2-ksrr-30-206]. Autologous chondrocyte implantation (ACI) could be one method to regenerate an articular cartilage defect. However, ACI is not applicable to articular cartilage defects in OA because chondrocytes from patients suffering from OA have totally different biological properties[@b3-ksrr-30-206]. Additionally, for large articular cartilage defects in patients with OA, an alternative cell source should be found. As an alternative, mesenchymal stem cells (MSCs) can be used to regenerative articular cartilage defects[@b4-ksrr-30-206]. MSCs can be isolated from a variety of sources, such as bone marrow (BM), adipose tissue, umbilical cord, amniotic fluid, dental pulp, synovial tissue, peripheral blood and skeletal muscles. It has been reported that the BM-derived MSCs contain progenitor cells of some mesenchymal tissues, such as cartilage and other tissues[@b5-ksrr-30-206]. Furthermore, BM is frequently used as a source for MSCs because they are relatively easy to isolate and they have a high potential for differentiation, even though it needs amount increases over several weeks in culture conditions for effective cellular dosage[@b6-ksrr-30-206]. Although there have been many studies on adipose-derived MSCs or adipose-derived stromal vascular fraction[@b7-ksrr-30-206]--[@b10-ksrr-30-206], few have assessed BM-derived MSCs and the results have been inconclusive. Previous studies have conducted a systematic review of the MSCs for the treatment of cartilage lesions[@b11-ksrr-30-206],[@b12-ksrr-30-206]; however, evidence is insufficient due to the different location of cartilage defect, different cell sources, different etiology, and different MSC dosage. Few direct comparisons of clinical scores on knee outcome scales and magnetic resonance imaging (MRI) outcomes between the baseline and final follow-up have been conducted in patients with knee OA treated with BM-derived MSCs. In addition, no meta-analyses on this subject have been published.

This meta-analysis was performed to assess clinical and MRI outcomes after surgery in patients with knee OA treated with BM-derived MSCs. It was hypothesized that BM-derived MSCs would lead to better clinical outcomes and MRI outcomes on final follow-up in these patients.

Materials and Methods
=====================

1. Data and Literature Sources
------------------------------

This study followed the Cochrane Review Methods. Multiple comprehensive databases, including MEDLINE (January 1, 1976 to September 30, 2017), EMBASE (January 1, 1985 to September 30, 2017), and the Cochrane Library (January 1, 1987 to September 30, 2017) were searched for studies of patients with knee OA treated with BM-derived MSCs which used the following assessments to compare clinical outcome: visual analog scale (VAS) for pain, Western Ontario McMaster Universities Arthritis Index (WOMAC), Lysholm score, Hospital for Special Surgery (HSS) score and range of motion (ROM). Selected studies also compared MRI outcomes using the whole-organ magnetic resonance imaging score (WORMS) and poor cartilage index (PCI). There was no language restriction, and filters of any kind were not applied for the strategy. The following keywords and their comprehensive combination and pertinent Medical Subject Headings (MeSH) were used to select the relevant articles: 'mesenchymal stem cells' OR 'mononuclear cells' OR 'bone marrow-derived mesenchymal stem cell' OR 'bone marrow stromal cells' OR 'muscular skeletal disease' OR 'osteoarthritis.'

After the initial electronic search, relevant articles and their bibliographies were searched manually.

2. Study Selection
------------------

Based on the title and abstract, two reviewers independently selected the relevant studies for full review. The full text copy of each article was reviewed if the abstract did not provide enough data to make a decision. Studies were included in the meta-analysis if they (1) assessed clinical outcomes, as determined by VAS for pain, WOMAC, Lysholm score, HSS score and ROM between the baseline and final follow-up, and MRI outcomes, as determined by WORMS and PCI between the baseline and final follow-up; (2) reported direct comparisons of surgical outcomes in patients with knee OA treated with intra-articular injections of BM-derived MSCs; (3) included data on at least one of the following 7 parameters: VAS for pain, WOMAC, Lysholm score, HSS score, ROM, WORMS and PCI. For the overall functional outcome measure, we combined comparable scores from different functional outcome tools when these tools scored disability: the higher the score, the greater the disability. Using the same method, we combined comparable scores of postoperative pain: the higher the score, the greater the pain. For WORMS, we recorded total WORMS score as assessed by cartilage thickness, signal intensity, and subchondral bone alteration and volume. The higher score values indicate more damage[@b13-ksrr-30-206]. PCI was evaluated using the mean T2 relaxation values sampled in 88 well-defined regions of interest: values at 100 present the worst possible PCI, and those at 5 or below are considered healthy[@b14-ksrr-30-206]; (4) fully reported the number of patients in each group (baseline and final follow-up groups) and the means and standard deviations for the 7 parameters; and (5) used adequate statistical methods to compare these parameters between groups. Studies were excluded if they (1) were not original articles; (2) were pre-clinical studies; (3) had missing or inadequate outcome data, such as standard deviations or ranges of values; and (4) used open surgery as the delivery method.

3. Data Extraction and Methodological Quality Assessment
--------------------------------------------------------

Two reviewers independently recorded data from each study using a predefined data extraction form and resolved any differences by discussion. Variables recorded included those associated with surgical outcomes, such as VAS for pain, WOMAC, Lysholm score, HSS score, ROM, WORMS and PCI. Sample size and the mean and standard deviation of surgical outcomes in each group were also recorded. If these variables were not included in the articles, the standardized mean difference (SMD) was calculated from the p-value and sample size.

Two reviewers independently assessed the methodological quality of the studies using interrupted time series analyses, as recommended by the Cochrane Effective Practical and Organisation of Care Group. Each study was judged based on seven standard criteria to detect whether the intervention has an effect significantly greater than the underlying secular trend. Any unresolved disagreements between reviewers were resolved by consensus or by consultation with a third investigator.

4. Data Synthesis and Analysis
------------------------------

The main outcomes of the meta-analysis were the SMD for overall clinical outcomes and MRI outcomes at the final follow-up compared to the baseline values due to use of several different measurement tools, including VAS for pain, WOMAC, Lysholm score, HSS score, ROM, WORMS and PCI. For all comparisons, SMD and 95% confidence interval (CI) were calculated for continuous outcomes. Heterogeneity was determined by estimating the proportion of between-study inconsistencies due to actual differences between studies, rather than differences due to random error or chance, using the I^2^ statistic, with values of 25%, 50%, and 75% considered low, moderate, and high heterogeneity, respectively. All statistical analyses were performed with RevMan ver. 5.3 (The Cochrane Collaboration, Copenhagen, Denmark). The risks of bias (low, high, or unclear) were independently assessed by two investigators. Subgroup analyses based on differences in the length of follow-up time were performed for pain scores in an attempt to explore a potential source of heterogeneity. As a result, two subgroups were created: follow-up more than 3 years and follow-up less than 3 years for pain scores. In addition, sensitivity analysis was conducted by excluding one of the eligible studies at a time; two studies with additional surgical procedures, such as cartilage treatment and osteotomy were included[@b15-ksrr-30-206],[@b16-ksrr-30-206]. Pooling of data was feasible for only two outcomes of interest, i.e., pain and function scores.

Results
=======

1. Identification of Studies
----------------------------

Details on study identification, inclusion, and exclusion are summarized in [Fig. 1](#f1-ksrr-30-206){ref-type="fig"}. An electronic search yielded 270 studies in PubMed (MEDLINE), 309 in EMBASE and 3 in the Cochrane Library. Two additional publications were identified through manual searching. After removing 152 duplicates, 432 studies remained; of these, 16 were excluded based on the abstract and full-text article review, and an additional eight studies were excluded because they had unusable information or made inappropriate group comparisons. This eventually resulted in 8 studies that were included in the meta-analysis[@b15-ksrr-30-206]--[@b22-ksrr-30-206].

2. Study Characteristics and Patient Populations
------------------------------------------------

The 8 studies we examined included 161 patients who underwent surgical treatment for knee OA with BM-derived MSCs. Five studies (5 randomized controlled trials \[RCTs\]) compared prospectively measured parameters, whereas the other three studies compared parameters measured by retrospective chart review. Seven studies reported pain score, six reported function score, four reported MRI score, and two reported ROM ([Table 1](#t1-ksrr-30-206){ref-type="table"}).

3. Quality and Publication Bias of the Included Studies
-------------------------------------------------------

The quality of the 8 studies included in the meta-analysis is summarized in [Table 2](#t2-ksrr-30-206){ref-type="table"}. Publication bias could not be assessed in these trials. Tests for funnel plot asymmetry are typically performed only when at least 10 studies are included in the meta-analysis. The meta-analysis included only 8 studies, and tests for asymmetry were not performed because these tests would not be able to differentiate asymmetry from chance.

4. Clinical Outcomes
--------------------

Of the 8 studies, 7 compared pain score and included 133 patients assessed at the baseline and 133 at the final follow-up. The standardized mean was 1.38 points lower at the final follow-up than at the baseline, and was significantly different between groups (95% CI, 0.89 to 1.87 points; p\<0.001; I^2^=62%) ([Fig. 2](#f2-ksrr-30-206){ref-type="fig"}). Two studies were assigned to the follow-up more than 3 years and five studies to the follow-up less than 3 years. The standardized mean in the more than 3 years of follow-up subgroup was 1.37 points lower at the final follow-up than at the baseline, and this difference was significant (95% CI, 0.33 to 2.40 points; p=0.01; I^2^=0%) ([Fig. 2](#f2-ksrr-30-206){ref-type="fig"}). Likewise, the value in the less than 3 years of follow-up subgroup was 1.40 points lower at the final follow-up than at the baseline, and this difference was significant (95% CI, 0.80 to 1.99 points; p\<0.001; I^2^=62%) ([Fig. 2](#f2-ksrr-30-206){ref-type="fig"}). Six studies, including 142 patients assessed at the baseline and 142 at the final follow-up, reported function score. The standardized mean was 1.38 points lower at the final follow-up than at the baseline, and there was significant difference between groups (95% CI, 0.70 to 2.07 points; p\<0.001; I^2^=83%) ([Fig. 3](#f3-ksrr-30-206){ref-type="fig"}). The results of sensitivity analysis were not materially differentiated from those of the original analysis ([Table 3](#t3-ksrr-30-206){ref-type="table"}).

5. ROM and MRI Outcomes
-----------------------

Of the 8 studies, two compared ROM and included 24 patients assessed at the baseline and 24 at the final follow-up. The standardized mean in ROM was −4.41° lower at the baseline than at the final follow-up (95% CI, −13.05° to 4.24°; p=0.32; I^2^=98%) ([Fig. 4](#f4-ksrr-30-206){ref-type="fig"}). Of the 8 studies, 4 compared MRI outcome and included 87 patients assessed with MRI at the baseline and 87 at the final follow-up. The standardized mean in MRI outcome was 0.62 lower at the final follow-up than at the baseline (95% CI, −0.16 to 1.40; p=0.12; I^2^=82%) ([Fig. 5](#f5-ksrr-30-206){ref-type="fig"}).

Discussion
==========

The main findings of the current meta-analysis verified that there were no significant differences in the tested ROM and MRI outcomes when compared to the baseline values in patients treated with BM-derived MSCs, whereas significant functional improvement and pain relief from the baseline were observed.

BM stromal cells (BMSCs) can be used as a cell suspension expanded by culture or just as BM concentrate (BMC). There are some differences between these two procedures. Expanded BMSCs require two-step procedures in addition to legal approval for the clinical application and cost disadvantages. In contrast, BMC contains a mixture of different red blood cells, platelets, and leukocytes[@b23-ksrr-30-206]. The adult MSC fraction is present in the leukocytes of the marrow, and their number is very limited compared to cultured MSCs. The marrow MSC and MSC precursors are extremely rare under normal conditions in human marrow before culture[@b24-ksrr-30-206]. Some authors suggested that for favorable chondrogenesis, the optimal count of MSCs per cm^3^ is an important factor[@b25-ksrr-30-206]. However, there is no study of comparison between BMSC and BMC treatment. The treatment using expanded BMSCs might be difficult to manage from a legal point of view because it might be considered as a pharmacological agent administration. In Korea, unlike BMC, expanded BMSCs need additional approval by the Korean Food and Drug Administration for the treatment of OA. In spite of the complicated procedure, whether the *in vitro* expansion influenced the effect of clinical application of MSCs was still unclear. For the fate of MSCs *in vivo*, current studies are not conclusive on this question: some have suggested MSCs differentiate and survive *in vivo* up to 6 months, while others suggest MSCs have a chondroinductive role of stimulating cartilage regeneration through trophic factors while slowly disappearing from the culture[@b26-ksrr-30-206]. BM-derived MSCs administered into knee have adhered to the surface of a damaged tissue, have differentiated into chondrocyte, and have expressed appropriate extracellular matrix protein, resulting in anatomic restoration on the damaged tissue with a significant relief of pain and disability[@b16-ksrr-30-206],[@b21-ksrr-30-206],[@b22-ksrr-30-206]. Our meta-analysis found that MRI outcomes did not show a significant difference from baseline despite the pain and functional advantages of injected BM-derived MSCs. The similar results for the MRI outcomes were likely due to the cell dose injected into the knee and culture conditions, suggesting that an optimal cell density and purity could affect the cell expansion. According to the animal study of Agung et al.[@b27-ksrr-30-206], the ideal number of MSCs that are needed for the regeneration of cartilage is known to be 1×10^7^, and a few clinical studies report that 1×10^7^ or more adult stem cells are ideal. Minimal criteria to define expanded multipotent human MSCs, as defined by the International Society for Cellular Therapy, include that they must be plastic-adherent when maintained in standard culture conditions, express CD105, CD73 and CD90, and lack expression of CD45, CD34, CD14 or CD11β, CD79α or CD19 and HLA-DR surface molecules, and they must be capable of differentiating into osteoblasts, adipocytes and chondroblasts *in vitro*[@b28-ksrr-30-206]. Among our included articles, 6 studies[@b16-ksrr-30-206],[@b19-ksrr-30-206]--[@b22-ksrr-30-206] met the ideal number of MSCs, 2 studies[@b17-ksrr-30-206],[@b18-ksrr-30-206] used less than 1×10^7^ MSCs. For MSC characterization, 2 studies[@b16-ksrr-30-206],[@b21-ksrr-30-206] did not describe the expression of CD. This could result in poor MRI outcomes than expected. In our meta-analysis, the tested ROM did not demonstrate any significant difference after BM-derived MSCs administration. These results may also be partly explained by small patient samples, which can lead to reduced statistical power and less precision. Thus, the ROM outcomes of the current meta-analysis could not be extended to all knee OA patients and further investigation through a future high volume study is necessary.

This study had several limitations. Of the 8 studies, 3 were observational comparison studies, which are prone to both systematic and random errors, suggesting some inherent heterogeneity due to uncontrolled bias. In addition, the heterogeneity of the included studies could be explained by slight differences in other factors affecting clinical outcomes, including the use of a wide variety of cell dose and cell processing methods[@b29-ksrr-30-206] as well as variability in functional and pain scores.

Conclusions
===========

This meta-analysis found no significant differences in the tested ROM and MRI outcomes in patients treated with BM-derived MSCs. On the other hand, they showed significant functional improvement and pain relief when compared with the baseline. Thus, BM-derived MSCs appear to be a viable alternative for patients with knee OA, although long-term and high-quality RCTs are needed to confirm the clinical benefits.
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###### 

Summary of Study Characteristics

  Study                                    Year   Study type   No. of patients (M/F)   Mean age (yr)   BMI (kg/m^2^)   Mean final F/U (mo)   Cell number     Amount (mL)   Delivery method   Concomitant procedure   Measured parameter
  ---------------------------------------- ------ ------------ ----------------------- --------------- --------------- --------------------- --------------- ------------- ----------------- ----------------------- --------------------
  Davatchi et al.[@b17-ksrr-30-206]        2016   OCS          4 (2/2)                 57.8            31.4            60                    8--9×10^6^      30            IA injection      No                      PS, ROM
  Emadedin et al.[@b18-ksrr-30-206]        2015   OCS          6 (0/6)                 54.5            NA              60                    5×10^5^         50            IA injection      No                      PS, FS
  Gupta et al.[@b19-ksrr-30-206]           2016   RCT          40 (12/28)              56.1            28.1            12                    25--150×10^6^   NA            IA injection      No                      PS, FS, MRIS
  Lamo-Espinosa et al.[@b20-ksrr-30-206]   2016   RCT          20 (12/8)               61.9            27.8            12                    10--100×10^6^   NA            IA injection      No                      PS, FS, ROM, MRIS
  Orozco et al.[@b21-ksrr-30-206]          2014   OCS          12 (6/6)                49              NA              12                    40×10^6^        86            IA injection      No                      PS, FS, MRIS
  Vangsness et al.[@b16-ksrr-30-206]       2014   RCT          36 (28/11)              46              NA              24                    50--150×10^6^   NA            IA injection      Meniscectomy            PS, FS
  Vega et al.[@b22-ksrr-30-206]            2015   RCT          15 (6/9)                52.6            NA              12                    40×10^6^        103           IA injection      No                      PS, MRIS
  Wong et al.[@b15-ksrr-30-206]            2013   RCT          28 (15/13)              53              23.8            24.8                  1.46×10^7^      49            IA injection      HTO+ microfracture      FS

BMI: bone mineral density, F/U: follow-up, OCS: observational case series, IA: intra-articular, PS: pain score, ROM: range of motion, NA: not available, FS: function score, RCT: randomized controlled trial, MRIS: magnetic resonance imaging score, HTO: high tibial osteotomy.

###### 

Risk of Bias Summary: Our Judgment on the Risk for Each Bias Item for Each Included Study

  Study                                    Year   Intervention independent of other change   Shape of the intervention effect prespecified   Intervention unlikely to affect data collection   Knowledge of the allocated interventions adequately prevented   Incomplete outcome data adequately addressed   Study free from selective outcome reporting   Study free from other risks of bias
  ---------------------------------------- ------ ------------------------------------------ ----------------------------------------------- ------------------------------------------------- --------------------------------------------------------------- ---------------------------------------------- --------------------------------------------- -------------------------------------
  Davatchi et al.[@b17-ksrr-30-206]        2016   −                                          −                                               −                                                 Unclear risk of bias                                            −                                              −                                             \+
  Emadedin et al.[@b18-ksrr-30-206]        2015   −                                          −                                               −                                                 Unclear risk of bias                                            −                                              −                                             \+
  Gupta et al.[@b19-ksrr-30-206]           2016   −                                          −                                               −                                                 Unclear risk of bias                                            −                                              −                                             \+
  Lamo-Espinosa et al.[@b20-ksrr-30-206]   2016   −                                          −                                               −                                                 Unclear risk of bias                                            \+                                             −                                             \+
  Orozco et al.[@b21-ksrr-30-206]          2014   −                                          −                                               −                                                 Unclear risk of bias                                            −                                              −                                             \+
  Vangsness et al.[@b16-ksrr-30-206]       2014   −                                          −                                               −                                                 Unclear risk of bias                                            \+                                             −                                             \+
  Vega et al.[@b22-ksrr-30-206]            2015   −                                          −                                               −                                                 Unclear risk of bias                                            −                                              −                                             \+
  Wong et al.[@b15-ksrr-30-206]            2013   −                                          −                                               −                                                 Unclear risk of bias                                            −                                              −                                             \+

−: low risk of bias, +: high risk of bias.

###### 

Sensitivity Analysis

  Study                                Year             Parameter        Before exclusion   After exclusion   Statistical significance                                                                   
  ------------------------------------ ---------------- ---------------- ------------------ ----------------- -------------------------- --------- -------------- -------------- ------- --------------- ---------------
  Vangsness et al.[@b16-ksrr-30-206]   2014             Pain score       1.38               0.89 to 1.87      5.51                       \<0.001   1.44           0.80 to 2.09   4.38    \<0.001         No difference
                                       Function score   1.38             0.70 to 2.07       3.97              \<0.001                    1.43      0.52 to 2.33   3.09           0.002   No difference   
  Wong et al.[@b15-ksrr-30-206]        2013             Function score   1.38               0.70 to 2.07      3.97                       \<0.001   1.17           0.52 to 1.83   3.52    \<0.001         No difference

MD: mean difference, CI: confidence interval.
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